---
title: "Informational Video Nudge Boosts Lung Cancer Screening Orders in Randomized Feasibility Trial"
id: "medrxiv-5-increasing-lung-cancer-screening-participation-using-an-informational-video"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-increasing-lung-cancer-screening-participation-using-an-informational-video"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1?rss=1"
published_at: "2026-09-01T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Informational Video Nudge Boosts Lung Cancer Screening Orders in Randomized Feasibility Trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-increasing-lung-cancer-screening-participation-using-an-informational-video
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1?rss=1)
- **Published At:** 2026-09-01T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A pragmatic randomized feasibility trial tested a brief **informational video nudge** to increase **lung cancer screening** (LCS) participation among eligible patients with upcoming primary care or pulmonology visits at Kaiser Permanente Colorado (KPCO). - Patients (N=1,093) were assigned to intervention (n=549) or usual care (n=544) by birth month; the intervention was delivered either via text message within 24 hours before an appointment or via text plus a QR code during rooming. - Primary outcomes included LCS ordering within 1 day of appointment and anytime during follow-up, plus baseline LCS completion (LDCT) and video engagement metrics. - Intervention patients had higher rates of LCS orders within 1 day (22.6% vs 16.4%, p=.010) and anytime during follow-up (32.6% vs 24.1%, p=.002) compared with usual care. - Baseline LCS-LDCT completion was 8.6% in the intervention group versus 5.7% in usual care (51% higher in intervention) but this difference did not reach statistical significance (p=.078). - Video engagement was modest: 93 individuals (17% of intervention group) viewed the video, producing 114 total views; mean watch time was 79% of the video; 82.5% of views were via text-message delivery rather than QR codes. - Multivariable logistic regression was used to evaluate factors associated with LCS ordering; details of model covariates and estimates beyond those reported were not provided in the source. - The trial was conducted March–October 2025 as a quality-improvement feasibility study and was determined by the institutional review board not to meet the regulatory definition of research; it was therefore not prospectively registered on ClinicalTrials.gov. - Based on observed effectiveness and feasibility, KPCO incorporated the behavioral nudge into standard clinical care in February 2026. - Data underlying the study are not publicly available due to protected health information; deidentified data may be available on request subject to institutional approvals.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=PTfMhRqpLkFvyuVJQnzpka2TxYp1nYy7RZRf9QL79Qc-1788318790.3821898-1.2.1.1-dj80sKM16jqzdWjV0AYnAzPNHYY4YrFtEA4QJN.cnlVENyRfzWZOjqGbuTOJs9OI) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Increasing Lung Cancer Screening Participation Using an Informational Video Nudge: A Randomized Feasibility Trial Kris F Wain, Nikki M Carroll, Andrew J Maclennan, Brian Hixon, Julie Steiner, Debra P Ritzwoller doi: https://doi.org/10.64898/2026.08.28.26361654 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Kris F Wain Kaiser Permanente Colorado * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kris%2BF%2BWain%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wain%20KF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKris%2BF%2BWain%2B) * For correspondence: kris.f.wain@kp.org Nikki M Carroll Kaiser Permanente Colorado * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nikki%2BM%2BCarroll%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Carroll%20NM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANikki%2BM%2BCarroll%2B) Andrew J Maclennan Kaiser Permanente Colorado * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrew%2BJ%2BMaclennan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Maclennan%20AJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrew%2BJ%2BMaclennan%2B) Brian Hixon Kaiser Permanente Colorado * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Brian%2BHixon%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hixon%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABrian%2BHixon%2B) Julie Steiner Kaiser Permanente Colorado * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julie%2BSteiner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Steiner%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJulie%2BSteiner%2B) Debra P Ritzwoller Kaiser Permanente Colorado * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Debra%2BP%2BRitzwoller%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ritzwoller%20DP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADebra%2BP%2BRitzwoller%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1289796/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1289796/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1289796/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1289796/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1289796/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Purpose: Lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces lung cancer mortality, yet screening participation remains low. We evaluated whether a brief informational video nudge delivered immediately before a scheduled clinical encounter increased LCS ordering and baseline LCS completion. Patients and Methods: We conducted a randomized feasibility trial within Kaiser Permanente Colorado from March through October 2025. LCS-eligible patients with an upcoming primary care or pulmonology appointment were assigned to intervention or usual care based on birth month. Intervention patients were split into two group, a group who received the LCS informational video nudge via text message within 24 hours of an eligible appointment; and second group who received the text plus a QR code video link during appointment rooming. Outcomes included LCS orders, baseline LCS-LDCT completion, and video engagement. Multivariable logistic regression was used to evaluate factors associated with LCS ordering. Results: Among 1,093 patients, 549 were assigned to intervention and 544 to usual care. Intervention patients were more likely to receive an LCS order within 1 day of their appointment (22.6% vs 16.4%; p=.010) and any time during follow-up (32.6% vs 24.1%; p=.002). Baseline LCS-LDCT completion was 51% higher in the intervention group, although the difference was not statistically significant (8.6% vs 5.7%; p=.078). Among the intervention group, 93 individuals (17%) viewed the video, generating 114 total views, and viewers watched an average of 79% of the video. Most views (82.5%) occurred through text-message delivery rather than QR codes. Conclusion: A brief, low-burden LCS informational video delivered immediately before a clinical encounter and integrated into existing workflows significantly increased LCS ordering and was associated with higher screening completion. Timely, scalable digital nudges may provide an effective strategy for improving LCS participation. Based on the observed effectiveness, feasibility, and efficiency of the intervention, KPCO incorporated the behavioral nudge into standard clinical care in February 2026. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial This pragmatic quality-improvement feasibility trial was not prospectively registered ClinicalTrials.gov because it was conducted as a health-system quality-improvement initiative and was determined by the institutional review board not to meet the regulatory definition of research. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Kaiser Permanente Interregional Institutional Review Board determined that this quality improvement initiative did not meet the regulatory definition of research; therefore, informed consent was not required I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The data underlying this study are not publicly available because they contain protected health information and are subject to Kaiser Permanente Colorado data governance and privacy requirements. Deidentified data may be available from the corresponding author upon reasonable request and subject to institutional review, data use agreements, and applicable regulatory approvals. ## Funder Information Declared Kaiser Foundation Health Plan of Colorado Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.27.26361507v1 "Persistence of psychotic experiences and clinical outcomes in adolescents at familial high risk of schizophrenia or bipolar disorder: The Danish High Risk and Resilience Study")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1 "Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial") Posted September 01, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/01/2026.08.28.26361654.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.28.26361654v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/01/2026.08.28.26361654.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Increasing Lung Cancer Screening Participation Using an Informational Video Nudge: A Randomized Feasibility Trial Kris F Wain, Nikki M Carroll, Andrew J Maclennan, Brian Hixon, Julie Steiner, Debra P Ritzwoller medRxiv 2026.08.28.26361654; doi: https://doi.org/10.64898/2026.08.28.26361654 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361654v1%26text%3DIncreasing%2520Lung%2520Cancer%2520Screening%2520Participation%2520Using%2520an%2520Informational%2520Video%2520Nudge%253A%2520A%2520Randomized%2520Feasibility%2520Trial "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361654v1%26t%3DIncreasing%2520Lung%2520Cancer%2520Screening%2520Participation%2520Using%2520an%2520Informational%2520Video%2520Nudge%253A%2520A%2520Randomized%2520Feasibility%2520Trial "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361654v1%26title%3DIncreasing%2520Lung%2520Cancer%2520Screening%2520Participation%2520Using%2520an%2520Informational%2520Video%2520Nudge%253A%2520A%2520Randomized%2520Feasibility%2520Trial%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361654v1%26title%3DIncreasing%2520Lung%2520Cancer%2520Screening%2520Participation%2520Using%2520an%2520Informational%2520Video%2520Nudge%253A%2520A%2520Randomized%2520Feasibility%2520Trial "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.28.26361654) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.28.26361654v1&count=horizontal&via=&text=Increasing%20Lung%20Cancer%20Screening%20Participation%20Using%20an%20Informational%20Video%20Nudge%3A%20A%20Randomized%20Feasibility%20Trial&counturl=www.medrxiv.org/content/10.64898/2026.08.28.26361654v1 "Tweet This") ## Subject Area * [Health Systems and Quality Improvement ](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (614) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (895) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (326) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4768) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1614) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15832) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6982) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1057) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4980) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1426) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1735) * [Hematology](https://www.medrxiv.org/collection/hematology) (581) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1334) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16243) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1161) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (663) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (720) * [Neurology](https://www.medrxiv.org/collection/neurology) (7191) * [Nursing](https://www.medrxiv.org/collection/nursing) (363) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1074) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1231) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1001) * [Oncology](https://www.medrxiv.org/collection/oncology) (3572) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1036) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (393) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (446) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (465) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (702) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1772) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (759) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5830) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9688) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2386) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1432) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1239) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (633) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (766) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (576) * [Surgery](https://www.medrxiv.org/collection/surgery) (766) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (302) * [Urology](https://www.medrxiv.org/collection/urology) (286) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content
## Related Clinical Research

- [No OS Benefit from Adding Chemotherapy to Immunotherapy in PD-L1 TPS ≥50% Advanced NSCLC: Agent-St](https://medichelpline.com/clinical-feed/medrxiv-1-no-overall-survival-benefit-with-adding-chemotherapy-to-immunotherapy-in-pd-l1.md)
- [AURORA: AI analysis of peripheral immune signatures predicting outcomes in extensive-stage SCLC](https://medichelpline.com/clinical-feed/medrxiv-22-aurora-analysing-and-understanding-responses-to-oncological-regimens-with.md)
- [Moderna and Merck’s cancer vaccine algorithm: what’s known and why it matters](https://medichelpline.com/clinical-feed/stat-news-1-what-s-in-merck-and-moderna-s-cancer-vaccine-algorithm.md)
- [Paclitaxel formulations and reported risk of macular oedema: real‑world JADER analysis](https://medichelpline.com/clinical-feed/plos-one-2-real-world-analysis-of-macular-oedema-associated-with-paclitaxel-formulations.md)
- [Exosome-mediated siRNA delivery in cancer: loading strategies, targeting approaches, and therapeut](https://medichelpline.com/clinical-feed/pubmed-42545436.md) (DOI: 10.1007/s40199-026-00631-z)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.